Modeling of in vitro drug activity and prediction of clinical outcome in acute myeloid leukemia

Journal of Clinical Pharmacology

Volumn 47, Issue 8, 2007, Pages 1014-1021

  Quartino, Angelica ^a   Karlsson, Mats O ^a   Freijs, Agneta ^a   Jonsson, Niclas ^a   Nygren, Peter ^b   Kristensen, Jörgen ^a   Lindhagen, Elin ^a   Larsson, Rolf ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Acute myelocytic leukemia; Cytosine arabinoside; Daunorubicin; Fluorometric microculture cytotoxicity assay; NONMEM

Indexed keywords

CYTARABINE; DAUNORUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG ACTIVITY; DRUG POTENCY; DRUG SENSITIVITY; FLUOROMETRY; HUMAN; HUMAN CELL; LOGISTIC REGRESSION ANALYSIS; PARAMETER; PROBABILITY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACUTE DISEASE; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL SURVIVAL; CYTARABINE; DAUNORUBICIN; HUMANS; LEUKEMIA, MYELOID; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PROGNOSIS; RETROSPECTIVE STUDIES; SPECTROMETRY, FLUORESCENCE; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 34447617147     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007302563     Document Type: Article

References (26)

1. Fruehauf JP In vitro assay-assisted treatment selection for women with breast or ovarian cancer. Endocr Relat Cancer. 2002 ; 9: 171-182.
2. Bosanquet AG, Nygren P., Weisenthal LM Cell culture drug resistance testing in leukemias and lymphomas. In: Kaspers et al, eds. Innovative Leukemia and Lymphoma Therapy. In press.
3. Weisenthal LM, Lippman ME Clonogenic and nonclonogenic in vitro chemosensitivity assays. Cancer Treat Rep. 1985 ; 69: 615-632.
4. Cortazar P., Johnson BE Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J Clin Oncol. 1999 ; 17: 1625-1631.
5. Samson DJ, Seidenfeld J., Ziegler K., Aronson N. Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol. 2004 ; 22: 3618-3630.
6. Stone RM, O'Donnell MR, Sekeres MA Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2004: 98-117.
7. Bosanquet AG Correlations between therapeutic response of leukaemias and in-vitro drug-sensitivity assay. Lancet. 1991 ; 337: 711-714.
8. Pieters R., Hongo T., Loonen AH, et al. Different types of non-P-glycoprotein mediated multiple drug resistance in children with relapsed acute lymphoblastic leukaemia. Br J Cancer. 1992 ; 65: 691-697.
9. Bosanquet AG, Burlton AR, Bell PB Parameters affecting the ex vivo cytotoxic drug sensitivity of human hematopoietic cells. J Exp Ther Oncol. 2002 ; 2: 53-63.
10. Broxterman HJ, Sonneveld P., Pieters R., et al. Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia? Leukemia. 1999 ; 13: 258-265.
11. von Hoff D. Human tumor cloning assays: application in clinical oncology and new antineoplastic agent development. Cancer Met Rev. 1988: 357-371.
12. Larsson R., Kristensen J., Sandberg C., Nygren P. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer. 1992 ; 50: 177-185.
13. Bird MC, Bosanquet AG, Forskitt S., Gilby ED Semi-micro adaptation of a 4-day differential staining cytotoxicity (DiSC) assay for determining the in-vitro chemosensitivity of haematological malignancies. Leuk Res. 1986 ; 10: 445-449.
14. Weisenthal LM, Dill PL, Finklestein JZ, Duarte TE, Baker JA, Moran EM Laboratory detection of primary and acquired drug resistance in human lymphatic neoplasms. Cancer Treat Rep. 1986 ; 70: 1283-1295.
15. Paalzow L. Therapeutical drug monitoring of anticancer drugs. In: Domellöf D, ed. Drug Delivery in Cancer Treatment. Berlin: Verlag ; 1990: 85-96.
16. Nygren P., Fridborg H., Csoka K., et al. Detection of tumor-specific cytotoxic drug activity in vitro using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. Int J Cancer. 1994 ; 56: 715-720.
17. Bennett JM, Catovsky D., Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976 ; 33: 451-458.
18. NONMEM: Nonlinear-Mixed Effects Modeling. Hanover, Md: Globomax.
19. Jonsson EN, Karlsson MO Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999 ; 58: 51-64.
20. Sheiner LB, Beal SL Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981 ; 9: 503-512.
21. Sheiner LB A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data. Clin Pharmacol Ther. 1994 ; 56: 309-322.
22. Danesi R., Fogli S., Gennari A., Conte P., Del Tacca M. Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet. 2002 ; 41: 431-44.
23. Lokich J., Anderson N. Dose intensity for bolus versus infusion chemotherapy administration: review of the literature for 27 antineoplastic agents. Ann Oncol. 1997 ; 8: 15-25.
24. DeVita V. Jr. Principles of chemotherapy. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott ; 1995: 276-300.
25. Alberts DS, Chen HS Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay. Prog Clin Biol Res. 1980 ; 48: 351-359.
26. Larsson R., Nygren P. Prediction of individual patient response to chemotherapy by the fluorometric microculture cytotoxicity assay (FMCA) using drug specific cut-off limits and a Bayesian model. Anticancer Res. 1993 ; 13 (5C): 1825-1829.